Adil Javed to Adult
This is a "connection" page, showing publications Adil Javed has written about Adult.
Connection Strength
0.256
-
T1 mapping from routine 3D T1-weighted inversion recovery sequences in clinical practice: comparison against reference inversion recovery fast field echo T1 scans and feasibility in multiple sclerosis. Neuroradiology. 2024 Oct; 66(10):1709-1719.
Score: 0.061
-
Reduction in ocrelizumab-induced infusion reactions by a modified premedication protocol. Mult Scler Relat Disord. 2019 Jan; 27:397-399.
Score: 0.041
-
Homonymous hemimacular thinning: a unique presentation of optic tract injury in neuromyelitis optica. J Neuroophthalmol. 2012 Jun; 32(2):150-3.
Score: 0.026
-
Type I interferon signature is high in lupus and neuromyelitis optica but low in multiple sclerosis. J Neurol Sci. 2012 Feb 15; 313(1-2):48-53.
Score: 0.025
-
Minor salivary gland inflammation in Devic's disease and longitudinally extensive myelitis. Mult Scler. 2008 Jul; 14(6):809-14.
Score: 0.020
-
COVID-19 in multiple sclerosis patients and risk factors for severe infection. J Neurol Sci. 2020 Nov 15; 418:117147.
Score: 0.012
-
Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis. J Neuroinflammation. 2020 Jun 15; 17(1):189.
Score: 0.012
-
Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment. PLoS One. 2018; 13(12):e0209326.
Score: 0.010
-
A 24-month advanced magnetic resonance imaging study of multiple sclerosis patients treated with alemtuzumab. Mult Scler. 2019 05; 25(6):811-818.
Score: 0.010
-
Antiglutamic acid decarboxylase 65 (GAD65) antibody-associated epilepsy. Epilepsy Behav. 2018 03; 80:331-336.
Score: 0.010
-
Long-term safety of rituximab induced peripheral B-cell depletion in autoimmune neurological diseases. PLoS One. 2018; 13(1):e0190425.
Score: 0.010
-
High resolution retinal scanning reveals regional structural differences between MS and NMOSD optic neuritis regardless of antibody status. J Neurol Sci. 2018 Jan 15; 384:61-66.
Score: 0.010
-
Natalizumab stabilizes physical, cognitive, MRI, and OCT markers of disease activity: A prospective, non-randomized pilot study. PLoS One. 2017; 12(4):e0173299.
Score: 0.009